Placebos exist in clinical trials to answer a deceptively simple question: did the treatment actually work, or would patients have improved anyway? Without a placebo group for comparison, researchers can’t separate a drug’s real biological effects from the natural course of a disease, the body’s own healing, or the powerful psychological impact of simply believing you’re being treated. The placebo-controlled trial is widely regarded as the gold standard for testing whether new treatments genuinely work.
The Core Problem Placebos Solve
Many conditions improve on their own. Symptoms fluctuate. Pain comes and goes. Depression lifts. Colds resolve. If you give 100 people a new drug and 60 of them feel better, that sounds impressive until you realize that maybe 40 of them would have felt better without any treatment at all. The only way to know is to compare the drug group against a group that received an identical-looking pill with no active ingredient.
This comparison strips away everything except the drug’s actual effect. When both groups go through the same experience (clinic visits, swallowing a pill, believing they might be receiving treatment), any difference in outcomes between the two groups can be attributed to the drug itself rather than to the ritual of being treated.
The Placebo Effect Is Surprisingly Strong
The placebo effect isn’t just “in your head” in the dismissive sense. It triggers measurable changes in brain chemistry. Research dating back to 1978 showed that placebo pain relief could be blocked by a drug that specifically counteracts the body’s natural painkillers, proving that placebos activate real opioid pathways in the brain. Brain imaging studies have since confirmed that when people expect a treatment to work, their brains release endorphins and dopamine in response. In Parkinson’s patients, placebo-induced expectation of improvement actually triggers dopamine release in the same brain region affected by the disease.
These aren’t subtle effects. In antidepressant trials, the average placebo response rate runs between 30% and 40%. For people with mild depression and a relatively short episode, that rate climbs to around 50%, often becoming virtually indistinguishable from the response to actual antidepressants. Pain trials show similar patterns: placebos consistently reduce reported pain intensity. This is precisely why researchers need a placebo group. If 55% of patients improve on a new antidepressant but 42% improve on placebo, the drug’s real added benefit is much smaller than the raw numbers suggest.
The severity and duration of illness matter too. People who have been depressed for more than a year tend to have placebo response rates under 30%, while those with episodes lasting less than three months respond to placebo about 50% of the time. These patterns help explain why some drugs appear to work dramatically in early trials but show modest benefits in larger studies with different patient populations.
Why “Blinding” Matters
A placebo does more than provide a comparison group. It enables blinding, which means keeping both patients and researchers unaware of who is getting the real drug. This prevents a cascade of biases that would otherwise contaminate results.
If patients know they’re receiving the actual treatment, they tend to report more improvement (or pay closer attention to side effects). If they know they’re on placebo, they may drop out of the trial, report more negatively, or seek treatment elsewhere. Researchers aren’t immune either. Doctors who know which patients are getting the real drug may unconsciously evaluate those patients more favorably, ask different follow-up questions, or interpret borderline results in the drug’s favor. The FDA specifically notes that blinding decreases biased observations, reduces uneven dropout rates, and allows for unbiased measurement, all of which are especially important when outcomes involve subjective measures like pain, mood, or fatigue.
Standard Placebos vs. Active Placebos
Most placebos are inert: a sugar pill, a saline injection, or a capsule filled with starch, designed to look, taste, and feel identical to the real drug. But there’s a flaw in this approach. If a drug causes noticeable side effects like dry mouth, drowsiness, or nausea, patients who experience nothing may correctly guess they’re in the placebo group. That unblinding reintroduces all the biases the placebo was supposed to prevent.
To address this, some trials use what’s called an active placebo. This is a substance that mimics the side effects of the drug being tested without providing its therapeutic benefit. By making the placebo group experience similar physical sensations, the trial maintains a more convincing blind. Active placebos are designed to imitate both the external characteristics and the internal sensations of receiving the treatment, making it harder for participants to figure out which group they’re in.
The Nocebo Effect: When Placebos Cause Harm
The placebo effect has a dark twin. In clinical trials, a substantial proportion of patients in placebo groups report negative side effects that match the known side effects of the real drug. This is the nocebo effect: adverse symptoms triggered by negative expectations rather than any active substance.
The likely culprit is the informed consent process. Before joining a trial, participants are told about potential side effects of the drug being studied. That information primes expectations. If you’re told a drug might cause headaches and nausea, you’re more likely to notice and report headaches and nausea, even if you’re taking a sugar pill. Research on the nocebo effect has demonstrated that it’s a genuine neurobiological phenomenon, producing detectable changes in the body. This pattern, where reported side effects in placebo groups mirror those associated with the actual drug, provides strong evidence that expectations alone can produce physical symptoms.
Placebo Run-In Periods
Some trials use a clever technique called a placebo run-in period. Before the trial officially begins, all enrolled patients receive a placebo for a set period, typically one to two weeks. Researchers then observe who responds strongly to the placebo and exclude those patients from the randomized phase of the trial.
The logic is straightforward. If someone improves dramatically on placebo alone, including them in the trial makes it harder to detect a real drug effect. By filtering out high placebo responders (and also people who don’t reliably take their pills), the run-in period increases the trial’s statistical power, its ability to detect a genuine treatment effect if one exists. It’s a way of sharpening the experiment so that the signal of a working drug doesn’t get lost in the noise of placebo responses.
When Placebos Aren’t Allowed
Placebos aren’t always ethical. The Declaration of Helsinki, the international standard for research ethics, sets clear boundaries. If a proven treatment already exists for a condition, new drugs must generally be tested against that existing treatment, not against a placebo. Giving someone a sugar pill when effective therapy is available means deliberately withholding care, which is unacceptable when the consequences could be serious or irreversible.
Placebos are considered acceptable in two situations: when no proven treatment exists for the condition being studied, or when there are compelling scientific reasons why a placebo comparison is necessary and participants won’t face risks of serious or irreversible harm from not receiving the standard treatment. A trial for a new acne medication, for example, might ethically use a placebo because going without treatment for a few months carries minimal risk. A trial for a new cancer drug almost certainly would not, instead comparing the new treatment against the current best option. The declaration emphasizes that extreme care must be taken to avoid abusing this flexibility.
This is why many modern trials use an “add-on” design: all participants receive standard treatment, and the experimental group gets the new drug on top while the control group gets standard treatment plus a placebo. Everyone receives care, and researchers can still measure whether the new drug adds anything beyond what’s already available.